Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 8, 2011, Pages 2394-2399

  Buchanan, John L ^a   Newcomb, John R ^a   Carney, David P ^a   Chaffee, Stuart C ^a   Chai, Lilly ^a   Cupples, Rod ^a   Epstein, Linda F ^a   Gallant, Paul ^a   Gu, Yan ^a   Harmange, Jean Christophe ^a   Hodge, Kathy ^a   Houk, Brett E ^a   Huang, Xin ^a   Jona, Janan ^a   Joseph, Smriti ^a   Jun, H Toni ^a   Kumar, Rakesh ^a   Li, Chun ^a   Lu, John ^a   Menges, Tom ^a   Morrison, Michael J ^a   Novak, Perry M ^a   Van Der Plas, Simon ^a   Radinsky, Robert ^a   Rose, Paul E ^a   Sawant, Satin ^a   Sun, Ji Rong ^a   Surapaneni, Sekhar ^a   Turci, Susan M ^a   Xu, Keyang ^a   Yanez, Evelyn ^a   Zhao, Huilin ^a   Zhu, Xiaotian ^a   more..

^a AMGEN INC   (United States)

Author keywords

Calu 6 xenograft; IGF 1R; Insulin like growth factor 1 receptor; Kinase; Pyrimidine; X ray cocrystal structure

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 391; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PYRIMIDINE DERIVATIVE; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL GROWTH; CELL PROTECTION; CRYSTAL STRUCTURE; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG SYNTHESIS; IN VIVO STUDY; MOUSE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

ANIMALS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUINOLINES; RECEPTOR, IGF TYPE 1; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79953271287     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.02.075     Document Type: Article

References (47)

1. M.N. Pollak, E.S. Schernhammer, and S.E. Hankinson Nat. Rev. Cancer 4 2004 505 and references cited therein
2. A.W. Tolcher, J. Sarantopoulos, A. Patnaik, K. Papadopoulos, C.-C. Lin, J. Rodon, B. Murphy, B. Roth, I. McCaffery, K.S. Gorski, B. Kaiser, M. Zhu, H. Deng, G. Friberg, and I. Puzanov J. Clin. Oncol. 23 2009 5800
3. P.J. Beltran, P. Mitchell, Y.-A. Chung, E. Cajulis, J. Lu, B. Belmontes, J. Ho, M.M. Tsai, M. Zhu, S. Vonderfecht, R. Baserga, R. Kendall, R. Radinsky, and F.J. Calzone Mol. Cancer Ther. 8 2009 1095
4. M.D. Wittman, U. Velaparthi, and D.M. Vyas Ann. Rep. Med. Chem. 44 2009 281
5. R. Li, A. Pourpak, and S.W. Morris J. Med. Chem. 52 2009 4981
6. M. Hewish, I. Chau, and D. Cunningham Recent Patents Anti-Cancer Drug Discov. 4 2009 54
7. A. Gualberto, and M. Pollak Oncogene 28 2009 3009
8. P.D. Ryan, and P.E. Goss Oncologist 13 2008 16
9. J. Rodon, V. DeSantos, R.J. Ferry Jr., and R. Kurzrock Mol. Cancer Ther. 7 2008 2575
10. M.M. Chitnis, J.S.P. Yuen, A.S. Protheroe, M. Pollak, and V.M. Macaulay Clin. Cancer Res. 14 2008 6363
11. S.R. Hubbard, and W.T. Miller Curr. Opin. Cell Biol. 19 2007 117
12. K. Imai, and A. Takaoka Nat. Rev. Cancer 6 2006 714
13. J.S.P. Yuen, and V.M. Macaulay Expert Opin. Ther. Targets 12 2008 589
14. S.J. Weroha, and P. Haluska J. Mammary Gland Biol. Neoplasia 13 2008 471
15. K. Paz, and Y.R. Hadari Comb. Chem. High Throughput Screening 11 2008 62
16. Y. Wang, Q.-S. Ji, M. Mulvihill, and J.A. Pachter Recent Results Cancer Res. 172 2007 59
17. R.D. Hubbard, and J.L. Wilsbacher ChemMedChem 2 2007 41
18. H. Hartog, J. Wesseling, H.M. Boezen, and W.T.A. van der Graaf Eur. J. Cancer 42 2007 1895
19. D.R. Clemmons Nat. Rev. Drug Disc. 6 2007 821
20. P. Sarma, R. Tandon, P. Gupta, S.G. Dastidar, A. Ray, B. Das, and I.A. Cliffe Expert Opin. Ther. Patents 17 2007 25
21. C. Garcia-Echeverria IDrugs 9 2006 415
22. F. Hofmann, and C. Garcia-Echeverria Drug Discovery Today 10 2005 1041
23. H. Zhang, and D. Yee Expert Opin. Invest. Drugs 13 2004 1569
24. Armistead, D. M.; Bemis, J. E.; Buchanan, J. L.; DiPietro, L. V.; Elbaum, D.; Habgood, G. J.; Kim, J. L.; Marshall, T. L.; Geuns-Meyer, S. D.; Novak, P. M.; Nunes, J. J.; Patel, V. F.; Toledo-Sherman, L. M.; Zhu, X. WO 01/25220.
25. m of ATP with respect to 1 μM of peptide substrate.
26. 50's were determined by comparing the level of thymidine incorporation found in the presence of compound compared to controls. (b) Compounds were routinely assessed in an assay measuring IGF-1-induced auto-phosphorylation of IGF-1Rβ and displayed good correlation with the proliferation results.
27. Armistead, D. M.; Bemis, J. E.; DiPietro, L. V.; Geuns-Meyer, S. D.; Habgood, G. J.; Kim, J. L.; Nunes, J. J.; Patel, V. F.; Toledo-Sherman, L. M. WO 01/60816.
28. Buchanan, J. L.; Chaffee, S.; Harmange, J.-C.; Novak, P. M.; Zhu, X. WO 03/018022.
29. Harmange, J.-C.; Booker, S.; Buchanan, J. L.; Chaffee, S.; Novak, P. M.; Van Der Plas, S.; Zhu, X. WO 03/018021.
30. The kinase domain of human IGF-1R (res 988 to 1286) with an N-terminal GST tag was expressed in insect cells and purified by immobilized glutathione affinity, anion exchange, and size exclusion chromatographies. The coordinates for the X-ray co-crystal structure of IGF-1R and 8 have been deposited in the PDB. The RCSB ID code is RCSB063987 and the PDB ID code is 3QQU.
31. Incubation of 3 with rat or human liver microsomes in the presence of NADPH identified O-demethylation as a major route of metabolism.
32. This strategy to improve cellular potency has been previously reported, for example: M.W. Martin, J. Newcomb, J.J. Junes, C. Boucher, L. Chai, L.F. Epstein, T. Faust, S. Flores, P. Gallant, A. Gore, Y. Gu, F. Hsieh, X. Huang, J.L. Kim, S. Middleton, K. Morgenstern, A. Oliveira-dos-Santos, V.F. Patel, D. Powers, P. Rose, Y. Tudor, S.M. Turci, A.A. Welcher, D. Zack, H. Zhao, L. Zhu, X. Zhu, C. Ghiron, M. Ermann, D. Johnston, and C.-G.P. Saluste J. Med. Chem. 51 2008 1637
33. (a) Male Sprague-Dawley rats were administered a solution of compound in DMSO at the indicated doses iv For oral dosing, a suspension of the compound in 1% Tween 80 and 1% HPMC in water was administered. Samples were collected over a 12-24 h period and analyzed for parent compound by LC-MS. (b) In vitro clearance (RLM and MLM) was not predictive of in vivo clearance, thus compounds were chosen for PK studies based on their enzyme and cellular potency profiles.
34. 6 cells per mouse). After 1 day, animals began continuous daily treatment with compound administered po, b.i.d at the indicated dose levels in 1% Tween 80 and 1% HPMC in water (3) or in 20% Captisol in PBS at pH 3.5 (26). Tumor volumes as established by caliper measurements were recorded twice per week, along with body weights as an index of toxicity. Blood glucose levels were recorded before dosing and once per week. Data are expressed as mean values plus or minus standard errors as a function of time. Statistical significance of observed differences was evaluated by repeated measures analysis of variance (RMANOVA) followed by Scheffe post hoc testing for multiple comparisons.
35. 50 (0.69 μM) determined in the Calu-6 proliferation assay.
36. (a) Hailey, J.; Maxwell, E.; Koukouras, K.; Bishop, W. R.; Pachter, J. A.; Wang, Y. Mol. Cancer Ther. 2002, 1, 1349; (b) 300 μg was chosen based on the maximal effect shown in an engineered IGF-1R-dependent 32D tumor xenograft model (Refs. 2b and 15). Data not shown.
37. F. Peruzzi, M. Prisco, M. Dews, P. Salomoni, E. Grassilli, G. Romano, B. Calabretta, and R. Baserga Mol. Cell. Biol. 19 1999 7203
38. Higher doses (200 mg/kg b.i.d.) were tolerated in an engineered IGF-1R-dependent 32D tumor xenograft study (Refs. 2b and 15), but were not tolerated in the longer term Calu-6 xenograft study. Data not shown.
39. (a) Blood glucose levels were checked at day 0, 9 and 21 within the Calu-6 xenograft study. No significant changes in blood glucose levels outside of the normal range were observed. (b) An insulin challenge test was done within the Calu-6 xenograft at day 17 of dosing. No significant differences were noted (at either the 30 or 100 mg/kg doses) in the ability of the animals to respond to insulin by modulating blood glucose. It is possible that at the 100 mg/kg dose of compound 26, the level of insulin receptor inhibition is not complete enough to result in metabolic effects.
40. Recent data suggests that the inhibition of both IGF-1R and InsR may be desirable. See for example: M. Pollak Nat. Rev. Cancer 8 2008 915
41. H. Zhang, D.H. Fagan, X. Zeng, K.T. Freeman, D. Sachdev, and D. Yee Oncogene 29 2010 2517
42. E. Buck, P.C. Gokhale, S. Koujak, E. Brown, A. Eyzaguirre, N. Tao, M. Rosenfeld-Franklin, L. Lerner, M.I. Chiu, R. Wild, D. Epstein, J.A. Pachter, and M.R. Miglarese Mol. Cancer Ther. 9 2010 1349
43. Clinical results for two advanced small molecule dual IGF-1R/InsR inhibitors in the clinic should help define the importance of InsR inhibition. See for example: M.D. Wittman, J.M. Carboni, Z. Yang, F.Y. Lee, M. Antman, R. Attar, P. Balimane, C. Chang, C. Chen, L. Discenza, D. Frennesson, M.M. Gottardis, A. Greer, W. Hurlburt, W. Johnson, D.R. Langley, A. Li, J. Li, P. Liu, J. Mastalerz, A. Mathur, K. Menard, K. Patel, J. Sack, X. Sang, M. Saulnier, D. Smith, K. Stefanski, G. Trainor, U. Velaparthi, G. Zhang, K. Zimmermann, and D.M. Vyas J. Med. Chem. 52 2009 7360
44. J.M. Carboni, M. Wittman, Z. Yang, F. Lee, A. Greer, W. Hurlburt, S. Hillerman, C. Cao, G.H. Cantor, J. Dell-John, C. Chen, L. Discenza, K. Menard, A. Li, G. Trainor, D. Vyas, R. Kramer, R.M. Attar, and M.M. Gottardis Mol. Cancer Ther. 8 2009 3341
45. M.J. Mulvihill, A. Cooke, M. Rosenfeld-Franklin, E. Buck, K. Foreman, D. Landfair, M. O'Connor, C. Pirritt, Y. Sun, Y. Yao, L.D. Arnold, N.W. Gibson, and Q.-S. Ji Future Med. Chem. 1 2009 1153
46. 1H NMR and were determined to be of >95% purity by reverse phase HPLC.
47. J.P. Wolfe, S. Wagaw, and S.L. Buchwald J. Am. Chem. Soc. 118 1996 7215